Overactive Bladder Treatment companies

Key Overactive Bladder Treatment Market Players:

 

The global OAB treatment market is highly competitive. Astellas, Pfizer, Allergan, and AbbVie dominate this market via flagship drugs such as Myrbetriq (mirabegron) and Vesicare, generics from Teva, and also neuromodulation devices marketed by Medtronic. In the competitive landscape, the new entrants from Japan, Sumitomo/Urovant with Gemtesa, Hisamitsu with OABLOK patch, and local manufacturers are developing diversified innovations into non-oral routes and device therapies. Indian generics companies such as Aurobindo, Dr. Reddy's Laboratories, and Sun Pharma reinforce the market on affordability and accessibility in emerging regions.

Here is a list of key players operating in the global market:

Company Name	Country	Estimated Market Share (2025)
Bayer AG	Germany	24.5%
Pfizer Inc.	USA	22.5%
Allergan plc / AbbVie Inc.	USA	10.5%
Teva Pharmaceutical Industries Ltd.	Israel	7.5%
Medtronic plc	Ireland / USA	5.5%
Endo International plc	USA	xx%
Urovant Sciences	USA	xx%
Sanofi S.A.	France	xx%
Johnson & Johnson (Janssen)	USA	xx%
Aurobindo Pharma Ltd.	India	xx%
Dr. Reddy’s Laboratories Ltd.	India	xx%
Sun Pharmaceutical Industries Ltd.	India	xx%
Viatris Inc.	USA	xx%
Mylan N.V.	USA / Europe	xx%
AbbVie (merged with Allergan)	USA	xx%

Source: PMDA, NIH, WHO

Below are the areas covered for each company in the overactive bladder treatment market:

• Company Overview
• Business Strategy
• Key Product Offerings
• Financial Performance
• Key Performance Indicators
• Risk Analysis
• Recent Development
• Regional Presence
• SWOT Analysis